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A middle-aged adult male with a mild form of tyrosi-
nemia II (Richner-Hanhart syndrome) is described. 
Treatment with a low-tyrosine diet caused a fall in 
plasma tyrosine and clearing of the hyperkeratosis of 
the soles. Liver biopsy of this patient revealed low but 
measurable levels of cytoplasmic tyrosine aminotrans-
ferase and elevated levels of the mitochondrial tyrosine-
metabolizing enzyme aspartate aminotransferase. It is 
hypothesized that these enzymes have been induced in 
sufficient amounts to account for the mild clinical course. 
Tyrosinemia II (Richner-Hanhart syndrome) is a rare syn-
drome with autosomal recessive inheritance in which tyrosine-
mia is causally related to keratitis, palmar-plantar erosions and 
hyperkeratosis, and occasionally to mental retardation. Most 
cases begin in early childhood and are not responsive to con-
ventional dermatological or ophthalmological therapies, al-
t hough spontaneous clinical remission of the condition may 
occur. The genetics, clinical details, an animal model, and the 
response of the syndrome to a low tyrosine diet have been 
recently r eviewed [1]. There is marked heterogeneity in the 
syndrom e in terms of the age of onset and severity of the 
symptoms although all cases are considered to be due to a 
deficien cy of hepatic tyrosine aminotransferase. We now report 
a severe a nd mild form of tyrosinemia II in the same kindred in 
Nort h Carolina . In this kindred, presumably all affected indi-
viduals h ave the same basic enzymatic defect. The results of 
the enzyme analysis of 2 of the major pathways of tyrosine 
metabolism in t h e liver of an adult with a mild form of the 
syndrome suggests a potential metabolic basis for the clinical 
h eterogeneity of the disease. 
PATIENT AND METHODS 
Clinical Features 
The patient is a 55-yr old male of slightly less than average intelli-
gence, who has been in good general health except for difficulty with 
his eyes, hands and feet. He had severe tearing and photophobia at age 
7-9 which prevented his obtaining schooling. Since that time no eye 
symptoms have been present. Since age 7-9 painful keratotic lesions 
have been present, predominantly on the feet. Intermittently, the 
lesions have been so painful that he walked on his knees rather than 
his feet. The lesions have not responded to multiple systemic and 
topical therapies although they have spontaneously abated occasion-
ally. When the patient was referred to Duke University Medical Center, 
tyrosinemia II was suspected and he was admitted for further studies 
and therapy. 
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Liver Enzyme Assays 
After informed consent, a percutaneous liver biopsy was performed 
and the specimen kept on ice and assayed within 2 hr. Control liver 
samples from autopsy specimens were kept on ice or stored at -20° 
before assay. Histological sections of the autopsy specimens and the 
liver of the patient with tyrosinemia were obtained and 2 histologically 
abnormal livers from the autopsy specimens are not included in these 
results. 
Standard assays were used to measure human liver tyrosine amino 
transferase (TAT) [2] and aspartate aminotransferase (AA T) [3]. Re-
agent grade chemicals from Sigma Chemicals, St. Louis, Mo. were used 
throughout. Approximately 250 mg of human liver (22 mg in the case 
of the tyrosinemia II patient) was 'weighed, minced with scissors, 
homogenized (on ice) with a glass/glass homogenizer (Kontes number 
22) in 4 volumes of 0.14 M KCl, and centrifuged at 31,000 Xg at 3°C for 
30 min. An aliquot of the supernatant was diluted 1:10 in 0.14 M KCI to 
assay for TAT activity, and the rest of the supernatant frozen. The 
pellet was suspended in 4 vol of 0.14 M KCI, homogenized briefly with 
the glass/glass homogenizer, an aliquot diluted 1:10 with 0.14 M KCI to 
assay for AAT, and the remainder frozen. 
TAT activity was assayed at 37°C in a shaking water bath. The 
buffer used throughout the assay for TAT was 0.2 M potassium phos-
phate, pH 7.3. The reaction mixture, at the time of assay, consisted of 
5.6 mM L-tyrosine, 3.7 mM diethyldithiocarbamate, 0.04 mM pyridoxyl-
5-phosphate, and 0.01 M a-ketoglutarate. Enzyme sample size was 0.07 
ml. After a 3 min preincubation of enzyme with the rest of the reaction 
mix, the assay was started by the addition of the a-ketoglutarate. 
Assays were stopped at 0, 20 and 40 min by the addition of 0.07 milO 
N NaOH and immediate mixing. After incubation at room temperature 
fo r an addit ional 30 min, the absorbance at 331 nm was recorded for 
each tube, using a Gilford Model 250 spectrophotometer. The velocity 
of the reaction was measured by the change in absorbance at 331 nm 
and is expressed as /lmoles p-hydroxyphenylpyruvate formed/ mg. pro-
tein/ min. A standard curve was derived using p-hydroxyphenylpyru-
vate in the reaction mixture and the molar extinction coefficient for p-
hydroxyphenylpyruvate was calculated as 1.73 X 10' . The value for the 
control tube to which NaOH was added before a-ketoglu tarate was 
subt racted from the tubes with active enzyme. 
The reaction mixture used in the assay of AAT contained 0.1 M 
triethanolamine, 64.5 mM sodium L-aspartate, and 6.85 mM a-ketoglu-
taric acid, adjusted to pH 7.5 with HC!. AAT was measured by the 
addition of 100 /ll aliquots of diluted enzyme to tubes containing 2.0 mI 
of reaction mixture; the complete reaction mix tures were put in to 
cuvettes in a Gilford Model 250 spectrophotometer, and incubated at 
room temperature. The assay was monitored continuously, and the 
absorbance at 260 nm was rcorded at 0 min and again at 30 min. 
Rates were calculated as /lmol oxaloacetate/30 min/ mg protein. 
Standards were obtained by measuring the absorption of oxaloacetate 
solu tion in the assay mixture at 260 nm. The molar extinction coefficient 
of oxaloacetate was 5.06 x 1O~ . 
The protein concent rations in the supernatants and resuspended 
pellets were measured by the technique of Lowry et a!. [4], and the 
total extractable protein in each fraction calculated and expressed as a 
percentage of the wet weight of the liver specimen. 
Plasma and urine amino acids were measured by gas chromatography 
on a Beckman GC-65 gas chromatograph with a linear temperature 
programmer and flame ionization detector according to the method of 
Gehrke et al and Roach [5]. 
RESULTS 
Clinical Studies 
Amino acid analysis confIrmed the clinical diagnosis of tyro-
s inemia (Fig 1) . Other la boratory tests including serum creati-
nine , SGOT, SGPT, electrophoresis of the plasma proteins, and 
liver scan wer e within normal limits. Ophthalmological exami-
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nation was normal. In the clinical research unit the patient was 
started on a low-tyrosine, low-phenylalanine diet, 3200 AB 
(Mead-Johnson), and his tyrosine levels moved toward normal 
levels (Fig 1). A short trial of therapy with Danocrine (200 mg/ 
day) and a trial with pyridoxine (800 mg/day in 4 divided doses) 
did not affect his blood tyrosine levels. Tyrosine was the only 
amino acid increased in the patient's urine and was as high as 
800 p.g/gm creatinine at its highest. Urine and plasma tyrosine 
levels decreased concurrently. While maintained on 3200 AB 
the pain in his soles resolved over days while the hyperkeratosis 
resolved over weeks (Fig 2A and B), although the plasma 
tyrosine levels remained 3 to 4 times greater than normal. 
Because the long-term consequences of this diet are unknown 
in adults (the patient is 40 yr older than any other patient with 
tyrosinemia II) , the response of his tyrosine level to increases 
in dietary protein were studied. After 3 days on a 10 gm protein 
diet his plasma level rose to 37 p.mol/l00 mI; after a subsequent 
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FIG 1. Response of Plasma Tyrosine to Therapy. The details of 
therapy are in the text. 
3 days of a 20 gm protein diet it rose to 68 p.mol tyrosine/l00 
mI. No eye or skin symptoms occurred with this increase in 
tyrosine level. 
The patient is related to a previously described patient with 
tyrosinemia [6]. The patients are fourth cousins with many 
common ancestors. Two of this patient's sibs have had clinical 
tyrosinemia II by history, and one (currently asymptomatic) sib 
has plasma tyrosine levels twenty times normal. Detailed ped-
igree and other genetic and biochemical studies from this large 
kindred are in progress. 
Biopsy of the patient's skin lesion showed hyperkeratosis. It 
was noticed during the biopsy procedure that the stratum 
corneum readily separated from the living epidermis. 
Hepatic Enzymes 
The patient's liver biopsy, which was normal histologically, 
had measurable levels of TAT in the supernatant and AA T in 
the mitochondrial fraction (Table). In all of the specimens 
assayed, enzyme activity was proportional to the duration of 
the assay and to the volume of homogenate in the reaction 
FIG 2. Response of Plantar Lesions to Therapy. A, Foot before 
therapy. Diffuse hyperkeratosis with areas of accentuation are present. 
B, Foot after 2 mo of a low-tyrosine low-phenylalanine diet. No topical 
therapies were used during this period. 
Hepatic tyrosine aminotransferase (TAT) and aspartic aminotransferase (AAT) activity 
Enzyme activity !IDloJes/30 min/ mg 
Patient Disease" 
TAT 
Tyrosinemia 133.3 
Control 1 Coronary Disease (16) 181.7 
2 Stroke (16) 158.3 
3 Renal Failure (18) 216.7 
4 Stroke (13) 150.0 
5 Pulmonary abscess (18) 100 
6 Renal failure (16) 550 
7 Duchenne 
Muscu lar dystrophy (2) 250 
7 /, 268 
8 Diabetes with 
glomerulosclerosis 
Post-nephrectomy (7) 516.7 
9 Coronary Disease (12) 183.3 
10 Coronary Disease (20) 200 
Control Data 
M ean 252.2 
and SD ±l37 
" Duration from time of death to autopsy in hours ( ). 
h Repeat assay of a new homogenate after storage of liver at -200 for 14 days. 
Enzyme activity and protein determined as detailed in Methods. 
Protein 
AAT 
7.3 
3.7 
3.6 
2.5 
2.4 
1.1 
2.1 
3.1 
1.8 
2.3 
1.2 
1.0 
2.35 
±0.95 
Protein as % of Wet Weight of Liver 
Specimen 
Supernantat Pellet 
2.9 4.2 
4.5 .3.0 
7.7 6.2 
7.6 1.6 
5.6 3.8 
7.3 6.3 
7.5 5.0 
9.1 6.5 
7.6 8.9 
4.8 3.0 
6.2 4.9 
6.4 7.3 
6.75 5.14 
±1.39 ±2.55 
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mixture. The TAT value in the tyrosinemic patient is within 1 
SD of the mean of control samples. The AAT value is more 
than 2 SD greater than normal. In the tyrosinerruc patient, the 
soluble protein in the cytoplasmic fraction is more than 2 SD 
below the mean for control livers, and the protein in the 
mitochondrial fraction is within 1 SD of the mean for the 
controls. In the studies of liver from patient 7, in which liver 
was frozen within 2 hr of death, and homogenization and assays 
performed on the day of autopsy and after 14 days of storage at 
-20°, comparable results were found. Two of the 3 patients 
with renal disease (patients 6 and 8) had elevated cytoplasmic 
tyrosine aminotransferase levels, and one patient (patient 3) 
had levels in the normal range. 
DISCUSSION 
Clinical Features 
This patient is the oldest reported patient with tyrosinemia 
II. At the time of study, although he had skin manifestations of 
the syndrome, he had no eye symptoms. The response of his 
skin lesions to the low tyrosine diet confirms their relationship 
to tyrosinemia. His palmar lesions are more diffuse than those 
previously described. This patient and the previously described 
North Carolina patient have several common ancestors and live 
within 10 miles of each other in a sparsely populated area of 
Eastern North Carolina. In view of the extreme rarity of tyro-
sinemia II, it is likely that both patients have the same genetic 
basis for their disease. Could this adult be a heterozygote rather 
than a homozygote? Four other heterozygotes have had normal 
plasma tyrosine levels [1] which makes heterozygosity unlikely. 
Furthermore, no known heterozygote has had symptoms. 
The clinical response of the plasma tyrosine to therapy was 
similar to that previously described in other patients; however, 
the skin lesions took longer to clear. Whether this difference is 
related to retention of toxic metabolites in the skin, age-related 
differences in plantar skin turnover, or other factors is unknown. 
The patient's clinical lesions were present when he had plasma 
tyrosine levels one-half those in the previously described patient 
[6]. Trials of pyridoxine (the cofactor of TAT) and Danocrine 
(an inducer of at least one liver protein, Cl esterase inhibitor) 
were not successful. The plasma tyrosine increased as the level 
of protein in the diet increased, suggesting diet liberalization 
will be difficult. 
Hepatic Enzyme Levels 
Tyrosine is metabolized by both a specific TAT in the cyto-
plasmic fraction, and by. a mitochondrial AAT' which utilizes 
tyrosine as a substrate. Liver TAT was definitely present in this 
patient although it was lower than most control levels. Liver 
AAT was definitely elevated. Repeat liver biopsy of the patient 
would be necessary to reconfirm these results but is not justified 
at this time. A large series of controls from normal liver biopsy 
specimens are necessary but this information is not available 
from the literature. The only studies of these enzymes in 
tyrosinemia II are those of Faull et al [9] and Fellman et al 
[7]. In the patient studied by Fellman et al [7] there was no 
soluble TAT and the mitochondrial TAT (presumably AAT) 
was normal compared with two control specimens. In the pa-
tient studied by Faull et al [9] (patient PR in their report) TAT 
was present; however, only one control specimen and method-
ology problems [10,11] prevent complete interpretation and 
comparison of that study with others. 
It is uncertain whether the increased levels of AAT and the 
presence of some TAT have allowed this patient to have lower 
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tyrosine levels than the other patients with the genetic trait, 
thus allowing a milder form of the disease. It is also uncertain 
whether the AAT levels are a compensatory response to the 
increased metabolic load for tyrosine. 
In experimental uremia, TAT levels increase [8] and this may 
be the reason for the higher TAT in some of the patients 
(Table) with renal disease. 
It is usually assumed that the specific TAT is the sole 
contributor to cytoplasmic TAT; however, definitive electro-
phoretic and immunologic proof of this consumption in human 
liver is lacking. Further physiochemical characterization of the 
enzyme abnormality(ies) in tyrosinemia II will be necessary to 
completely understand the enzymatic basis of this disease. 
Since in many genetically determined enzymatic deficiencies 
the enzyme is present at low levels, it is possible that this 
patient may have in fact induced some of his defective enzyme. 
Complete understanding of the in vivo metabolic fate of 
tyrosine in tyrosinemia II will require metabolic balance studies 
with suitably labeled substrates [9]. Various compensatory 
metabolic pathways can be identified, and by understanding 
these alternate routes of tyrosine metabolism it may be possible 
to devise alternatives to strict diet therapy. 
We greatly appreciate the help of the Clinical Research Units (sup-
ported by grant RR-30 General Clinical Research Centers Program, 
Division of Research Resources of the National Institutes of Health) 
especially the dietitians and the pathology department for obtaining 
liver specimens. We thank Mead Johnson Company for supplying 3200 
AB for this patient. 
NOTE ADDED IN PROOF 
A recent report confirms the liver AAT increase with this syndrome. 
An 18 month-old with the complete syndrome has been reported by M. 
Larregue and colleagues (Ann Dermatolvenerol 106:53-62, 1979). Liver 
biopsy revealed no TAT but elevated mitochondrial tyrosine amino-
transferase (23 mU/mg protein in the patient; compared with values of 
10 and 12 mU/mg in controls) . 
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